174 related articles for article (PubMed ID: 38051855)
1. INDIVIDUAL ARTICLE: Management of Prurigo Nodularis.
Elmariah SB; Tao L; Valdes-Rodriguez R; Laquer V
J Drugs Dermatol; 2023 Dec; 22(12):SF365502s15-SF365502s22. PubMed ID: 38051855
[TBL] [Abstract][Full Text] [Related]
2. Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus.
Elmariah S; Kim B; Berger T; Chisolm S; Kwatra SG; Mollanazar N; Yosipovitch G
J Am Acad Dermatol; 2021 Mar; 84(3):747-760. PubMed ID: 32682025
[TBL] [Abstract][Full Text] [Related]
3. A critical review of dupilumab for adult patients with prurigo nodularis.
Biazus Soares G; Yosipovitch G
Expert Rev Clin Immunol; 2024 Mar; 20(3):249-254. PubMed ID: 37811660
[TBL] [Abstract][Full Text] [Related]
4. Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis.
Williams KA; Roh YS; Brown I; Sutaria N; Bakhshi P; Choi J; Gabriel S; Chavda R; Kwatra SG
Expert Rev Clin Pharmacol; 2021 Jan; 14(1):67-77. PubMed ID: 33191806
[No Abstract] [Full Text] [Related]
5. INDIVIDUAL ARTICLE: Prurigo Nodularis: Current Clinicopathologic Overview and Psychodermatological Perspectives.
Issa NT; Riva H; Jafferany M
J Drugs Dermatol; 2023 Dec; 22(12):SF365502s6-SF365502s11. PubMed ID: 38051853
[TBL] [Abstract][Full Text] [Related]
6. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response.
Husein-ElAhmed H; Steinhoff M
J Dermatolog Treat; 2022 May; 33(3):1547-1553. PubMed ID: 33200955
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of biologics in prurigo nodularis.
Müller S; Bieber T; Ständer S
Expert Opin Biol Ther; 2022 Jan; 22(1):47-58. PubMed ID: 34289753
[TBL] [Abstract][Full Text] [Related]
8. Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis: A Secondary Analysis of a Randomized Clinical Trial.
Kimel M; Zeidler C; Kwon P; Revicki D; Ständer S
JAMA Dermatol; 2020 Dec; 156(12):1354-1358. PubMed ID: 32936233
[TBL] [Abstract][Full Text] [Related]
9. A critical evaluation of nemolizumab for prurigo nodularis.
Brooks SG; Yosipovitch G
Expert Rev Clin Immunol; 2024 Jun; 20(6):577-587. PubMed ID: 38217530
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of dupilumab in prurigo nodularis in elderly patient.
Giura MT; Viola R; Fierro MT; Ribero S; Ortoncelli M
Dermatol Ther; 2020 Jan; 33(1):e13201. PubMed ID: 31856368
[TBL] [Abstract][Full Text] [Related]
11. Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments.
Müller S; Zeidler C; Ständer S
Am J Clin Dermatol; 2024 Jan; 25(1):15-33. PubMed ID: 37717255
[TBL] [Abstract][Full Text] [Related]
12. Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need.
Pereira MP; Basta S; Moore J; Ständer S
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2224-2229. PubMed ID: 29869425
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab Treatment for Prurigo Nodularis and Pruritis.
Tanis R; Ferenczi K; Payette M
J Drugs Dermatol; 2019 Sep; 18(9):940-942. PubMed ID: 31524352
[TBL] [Abstract][Full Text] [Related]
14. Dupilumab for the Treatment of Prurigo Nodularis.
Alkhaleefa A; Woo TE; Parsons L
Skin Therapy Lett; 2023 Nov; 28(6):7-9. PubMed ID: 38016088
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of pruritus in prurigo nodularis.
Shao Y; Wang D; Zhu Y; Xiao Z; Jin T; Peng L; Shen Y; Tang H
Front Immunol; 2023; 14():1301817. PubMed ID: 38077377
[TBL] [Abstract][Full Text] [Related]
16. A real-world observational study of dupilumab treatment in adult patients with prurigo nodularis.
Zhang Z; Li S; Wang Y; Zhao J
An Bras Dermatol; 2023; 98(4):440-448. PubMed ID: 36966024
[TBL] [Abstract][Full Text] [Related]
17. A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis.
Nilforoushzadeh MA; Heidari N; Ghane Y; Heidari A; Hajikarim-Hamedani A; Hosseini S; Jaffary F; Najar Nobari M; Tavakolzadeh P; Najar Nobari N
Inflammopharmacology; 2024 Apr; 32(2):991-1003. PubMed ID: 38332383
[TBL] [Abstract][Full Text] [Related]
18. Prurigo nodularis: new insights into pathogenesis and novel therapeutics.
Liao V; Cornman HL; Ma E; Kwatra SG
Br J Dermatol; 2024 May; 190(6):798-810. PubMed ID: 38345154
[TBL] [Abstract][Full Text] [Related]
19. The effectiveness and safety of dupilumab in the management of refractory prurigo nodularis in 45 Chinese patients: A real-life observational study.
Fang HY; Lian CH
J Dermatol; 2023 Aug; 50(8):1084-1087. PubMed ID: 37088954
[TBL] [Abstract][Full Text] [Related]
20. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]